RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
India’s Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China’s speeded-up approval process to register products that are already approved elsewhere. Natco has decided to diversify away from the US and de-risk its strategy by emphasizing markets such as China, Brazil and Canada. Natco will now spend about 60%-70% of its R&D investment in developing countries, leaving just 30% for the US. By making the change, Natco joins other India pharmas, Cipla and Sun Pharma, who have also announced China plans. Source: China Biotoday
